HPTN 083: Incident Infections and Emergent Resistance in MSM and TGW Receiving Cabotegravir Long-Acting PrEP

March 6-10, 2021; Virtual
Longitudinal analysis of HIV infections, viral load, cabotegravir concentrations, and emergent resistance in HPTN 083 demonstrated the importance of prompt diagnosis and initiation of ART to avoid resistance in cases of breakthrough infection with long-acting cabotegravir as PrEP.
Format: Microsoft PowerPoint (.ppt)
File Size: 382 KB
Released: March 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Clinical Care Options’ (CCO) commentary from a person with HIV on what it was like living through the COVID-19 pandemic as a long-term HIV survivor

person default Frank Primavera Released: June 9, 2021

Slides from CCO: Switching ART in HIV: 3-drug therapy, oral 2-drug options, long-acting injectable 2-drug regimens, single tablet regimens (STRs)

Daniel R. Kuritzkes, MD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: June 7, 2021

Latesha Elopre and CCO: starting HIV pre-exposure prophylaxis (PrEP). DISCOVER study, CDC guidance, racial/ethnic disparities, overcoming barriers

Latesha Elopre, MD, MSPH Released: June 7, 2021

Slides from Latesha Elopre and CCO: starting HIV preexposure prophylaxis (PrEP). DISCOVER study, CDC guidance, racial/ethnic disparities, overcoming barriers.

Latesha Elopre, MD, MSPH Released: June 7, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue